Newsletter No. 102 -- April 2008
Amendment to PAR-07-214: Academic-Industrial Partnerships for Development and Validation of In Vivo Imaging Systems and Methods for Cancer Investigations (R01) (NCI) (NOT-CA-08-014)
The purpose of this Notice is to announce that NCI will accept eligible renewal (Type 2) R01 applications for grants made in connection with PAR-07-214, Academic-Industrial Partnerships for Development and Validation of In Vivo Imaging Systems and Methods for Cancer Investigations (R01).
URL for PAR-07-214: http://grants.nih.gov/grants/guide/pa-files/PAR-07-214.html
NIBIB Interfaces Initiative for Interdisciplinary Graduate Research Training (T32) (RFA-EB-08-003)
Application Receipt Date(s): June 17, 2008
The NIBIB solicits grant applications for recently established interdisciplinary research training programs that integrate the biomedical sciences with the physical sciences and/or engineering.
Probes and Instrumentation for Monitoring and Manipulating Nervous System Plasticity (R01) (RFA-MH-09-030)
Application Receipt Date(s): September 16, 2008
Applications are solicited for support of projects that will develop probes, instrumentation, and other tools for understanding, monitoring, and manipulating nervous system plasticity. This FOA will focus on the development of tools or techniques that will significantly advance the current state of the art in neuroplasticity research. Although applications will not be restricted to a particular type of technology, we are especially interested in applications that seek to harness the ability to assess and manipulate activity with exquisite subcellular resolution, and in cells specified by their circuit connectivity and/or transmitter phenotype. Among the topics considered responsive this FOA are improved equipment for imaging or other monitoring techniques.
Cancer Education Grants Program (R25) (NCI)(PAR-08-120)
Application Receipt/Submission Date(s): Standard dates apply
This FOA encourages applications for the development of: (i) innovative cancer education programs; and (ii) cancer research dissemination projects that can be completed within 5 years. Specifically, the types of Cancer Education Grant Programs (CEGPs) that may be supported include: (1) innovative educational programs intended to motivate biomedical and other health science students to pursue cancer related careers; (2) short courses to update cancer research scientists in new scientific methods, technologies and findings; (3) training of cancer care clinicians and community health care providers in evidence-based cancer prevention and control approaches; and (4) development of effective innovative education (dissemination) approaches to translate knowledge gained from science (discovery) into public health, and community applications (delivery).
NINDS Institutional Center Core Grants to Support Neuroscience Research (P30) (PAR-08-116)
Application Receipt/Submission Date(s): Standard dates fpr P series apply NINDS Center Core Grants will support centralized resources and facilities shared by investigators with existing NINDS-funded research projects. Each Center will be composed of one or more research cores, each of which will enrich the effectiveness of ongoing research, and promote new research directions. Among the examples of research cores given are imaging (MRI, PET, MEG, NIRS) cores.
Prescription Drug Misuse (R01) (NIDA, NIMH)(R01: PA-08-127; R21: PA-08-128; R03:PA-08-129)
Application Receipt/Submission Date(s): Standard dates apply.
NIDA and NIMH invite research applications to reduce prescription drug misuse while supporting the appropriate medical use of therapeutic agents that carry an abuse liability. A range of research is being solicited to combat prescription drug misuse-from epidemiologic research specifying the extent and nature of the problem (including physical and mental health and social consequences) as it relates to each specific drug and identifying determinants and trajectories of use. Across levels of analysis and research domains, there is also an interest in stimulating development and integration of technologies (for example, from genetic, imaging, proteomic, metabolic information and approaches) to observe and understand the etiology and biological and behavioral mechanisms associated with prescription drug abuse.
URL (R01:PA-08-127): http://grants.nih.gov/grants/guide/pa-files/PA-08-127.html
URL (R21:PA-08-128): http://grants.nih.gov/grants/guide/pa-files/PA-08-128.html
URL (R03:PA-08-129): http://grants.nih.gov/grants/guide/pa-files/PA-08-129.html
Notice of Amendment to the Resubmission Restriction, Institutional Clinical and Translational Science Award (U54) (NCRR) (RFA-RM-08-002)
The NCRR will allow, effective immediately, previously unsuccessful applicants the option to resubmit amended applications in response to RFA-RM-08-002. A resubmission application should include a 3-page introduction that describes the responses made to the previous summary statement. Reviewers will be provided copies of the previous summary statement as part of their review of the resubmitted application.
Previously unsuccessful applications should be submitted as new applications when the new funding guidelines have resulted in significant changes in the scope of the application.
URL for RFA-RM-08-002: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-08-002.html
Exploratory/Developmental Grant for Complementary and Alternative Medicine (CAM) Studies of Humans (R21) (NCCAM, NCI, NIA) (PAR-08-135)
Application Receipt/Submission Date(s): Standard dates apply.
One of the primary missions of NCCAM is to advance CAM science. Understanding the safety, efficacy and effectiveness of CAM approaches may facilitate their integration into conventional health care practices. However, prior to conducting clinical trials to determine definitively efficacy and effectiveness, there is important information that needs to be generated. A variety of study designs (e.g., observational, case control, cohort studies, randomized clinical studies) may be used to obtain this information. … Examples of research that would be considered include studies to develop and validate testing of biological, physiological, and behavioral outcome measures in humans for use in CAM clinical research, of which optimization of imaging methods and enzymatic assays is an example.
2009 HHMI Early Career Scientist Competition
Letter of Intent Receipt Deadline: April 30, 2008, 2 PM ET
Application Receipt Deadline: June 10, 2008, 2 PM ET
The Howard Hughes Medical Institute (HHMI) is pleased to announce a national competition to select as many as 70 outstanding early career scientists.
CIP DCIDE PROGRAM
The Cancer Imaging Program of the NCI requests submissions for its Development of Clinical Imaging Drugs and Enhancers (DCIDE) initiative. The goal is the rapid movement of promising, novel cancer imaging enhancers or molecular probes from the laboratory to proof of principle clinical trials. See the web site for details.
GUEST AUTHOR OPPORTUNITIES IN THE NIH MICAD DATABASE
The Molecular Imaging and Contrast Agent Database (MICAD) program has been developed as a key component of the NIH Molecular Imaging Roadmap to provide freely accessible online scientific information on in vivo molecular imaging and contrast agents. To accelerate expansion of the database to include all published agents, the MICAD program has implemented a procedure for members of the imaging community to write and submit entries (chapters) as guest authors to the database. All members of the imaging community are encouraged to consider this guest author opportunities. For further information, please contact the MICAD staff at email@example.com. Individual guest authors will be provide with detailed instructions, style guidelines, and a chapter template. The name of the contributing author(s) will be acknowledged and included in the MICAD online publication.
Request for Information: NIH Public Access Policy (NOT-OD-08-060)
The NIH requests input from the community regarding the NIH Policy on Enhancing Public Access to Archived Publications Resulting From NIH-Funded Research (NIH Public Access Policy).
Optical Society of America, March 16-19, 2008, Hilton St. Petersburg Bayfront, St. Petersburg, FL,
NIH Regional Seminars in Program Funding and Grants Administration for 2008 (NOT-OD-08-022)
March 25-27, 2008 - University of Texas Health Science Center, San Antonio, Texas.
June 18-20, 2008 - University of Illinois at Chicago.
ISMRM 16th Scientific Meeting & Exhibition
May 3-9, 2008, Toronto, ON, Canada.
SCAW IACUC-Advanced Workshop on May 7, 2008 in Bethesda, MD (NIH) (NOT-OD-08-062)
33rd International Symposium on Ultrasonic Imaging and Tissue Characterization
May 14-16, 2008, Rosslyn Westpark Hotel, Arlington, Virginia
Society for Imaging Informatics in Medicine (SIIM)
2008 Annual Meeting, May 15-18, 2008, Washington State Convention and Trade Center, Seattle, WA
American Society of Neuroradiology
46th Annual Meeting, May 31 - June 5, 2008, Ernest N Morial Convention Center, New Orleans, LA
Society of Nuclear Medicine 2008 Annual Meeting
June 14-18, 2008, Ernest N Morial Convention Center, New Orleans, LA
2008 AAPM Summer School
The Physics and Applications of PET/CT Imaging, June 25-27, 2008, Edwin Hornberger Conference Center, Houston, TX
CARS 2008 22nd International Congress and Exhibition
June 25-28, 2008, Hotel NH Constanza, Barcelona Spain
50th AAPM Annual Meeting
July 27-31, 2008, George R Brown Convention Center, Houston, TX
World Molecular Imaging Congress
Sponsored by the Society for Molecular Imaging (SMI), the Academy of Molecular Imaging (AMI), the European Society for Molecular Imaging (ESMI) and the Federation of Asian Societies for Molecular Imaging (FASMI)
September 10-13, 2008, Nice, France
If you wish to remain on the list, no action is necessary. If you wish to be added to the list, please contact Dr Barbara Croft by return e-mail (firstname.lastname@example.org). Please include your complete mailing address, title, phone and fax numbers.
Cancer Imaging Program,
Division of Cancer Treatment and Diagnosis,
NCI 6130 Executive Boulevard - MSC-7412
Bethesda, MD 20892-7412
Tel: 301 496 9531
Fax: 301 480 3507